Evercore ISI Starts Aclaris Therapeutis (ACRS) at Outperform, 'could trade 300% up on positive zunsemetinib data'
Tweet Send to a Friend
(Updated - October 3, 2023 8:21 AM EDT)
Evercore ISI analyst Gavin Clark-Gartner initiates coverage on Aclaris Therapeutis (NASDAQ ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Evercore ISI analyst Gavin Clark-Gartner initiates coverage on Aclaris Therapeutis (NASDAQ ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
